Researchers at Oregon Health & Science University have made a groundbreaking discovery in animal models that a one-time treatment regimen can permanently clear HIV from newborns. The study's findings have the potential to advance quickly to human clinical trials, offering new hope for millions of people worldwide who require lifelong t...
Scientists at La Jolla Institute for Immunology and Scripps Research have developed an HIV vaccine that trains immune cells to see past HIV's defenses. The vaccine resulted in the best HIV-fighting antibody response ever seen in primates, with human trials now underway.
Researchers found that Ebola virus can persist in cerebral organoids for up to 120 days, infecting various cell types, including neurons and astrocytes. The virus can trigger local inflammation and lead to disease relapses in survivors, highlighting the need for improved treatments.
Scientists at La Jolla Institute for Immunology have characterized human antibodies capable of neutralizing measles virus. The new panel of human antibodies may form the basis for future medical therapies against measles infection, with a study showing a 500-fold lower viral load in a rodent model.
Researchers used AI to identify a new viral surface protein that triggers the production of neutralizing antibodies, offering a breakthrough for developing effective vaccines and antibody therapies. The discovery could also provide insights into treating smallpox, a related virus posing a bioterrorism risk.
Researchers identified specific antibody features that limit Mtb growth, revealing critical insights into antibody-immune cell interactions. The study lays groundwork for potential antibody-based therapies or vaccines against tuberculosis, an urgently needed treatment for the deadly infectious disease.
Scientists have engineered a monoclonal antibody that protects mice from a lethal dose of influenza A with sticky staying power. The new molecule combines specificity and broad binding capacity, adhering to the lung lining and blocking infection in mice.
Scientists have developed the most broadly effective antivenom to date, neutralizing the neurotoxins of 19 deadly snakes including black mambas and king cobras. The antivenom combines protective antibodies and a small molecule inhibitor, offering a potential universal solution for snakebite victims.
A new collaboration aims to develop an affordable and accessible monoclonal antibody therapeutic for CCHFV, treating thousands globally. USAMRIID discovered the antibody in mice, and LifeArc is supporting development of a fully humanized antibody.
Researchers developed a new, three times more effective version of the antibothropic serum used to treat snake venom poisoning. The improved serum had increased neutralizing antibodies and fewer proteins associated with side effects, resulting in greater potency and reduced risk of adverse reactions.
Researchers have made significant discoveries about the role of GP38 in viral infections and pathogenesis, highlighting its potential as a target for vaccines and medical countermeasures. Non-neutralizing GP38-specific antibodies have shown protective efficacy against lethal challenge, reducing circulating GP38 and vascular leak.
A study published in Human Gene Therapy found that over half of individuals with Niemann-Pick disease type C1 lacked neutralizing antibodies against AAV2 and AAV9. This absence of antibodies may impact the effectiveness of gene therapy treatments for this rare disorder.
Researchers have identified powerful antibodies capable of neutralizing a wide range of norovirus strains, paving the way for designing a broadly effective norovirus vaccine. The discovery brings us closer to a vaccine that could provide lasting protection and prevent devastating effects of norovirus outbreaks.
A broadly neutralizing antibody has been shown to protect monkeys against severe H5N1 avian flu disease. The antibody's stable structure ensures it can withstand virus variants, providing universal protection against a globally spreading airborne infection. Serum levels of the antibody remained stable for up to 12 weeks.
Researchers developed a nanoparticle-based vaccine that generates antibodies targeting conserved regions of sarbecovirus receptor-binding proteins, offering broader protection against multiple strains. The vaccine demonstrated strong antibody responses and protection in animal studies against diverse SARS-CoV-2 and other sarbecoviruses.
Researchers at NIH have identified a novel class of anti-malaria antibodies that target previously untargeted regions of the parasite. These antibodies have shown promise in providing protection against malaria parasites in animal models and could lead to new prevention methods.
A novel vaccine design has demonstrated robust immune response and broad neutralization of HCV strains in mouse models. The innovative approach employs epitope-focused immunogens, which could pave the way for an effective HCV vaccine, potentially limiting its global spread.
Researchers have discovered a monoclonal antibody capable of targeting multiple SARS-CoV-2 variants, including recent Omicron strains. K4-66's exceptional ability to adapt to the virus's frequent mutations makes it a promising candidate for vaccine and therapy development.
Researchers at Fred Hutchinson Cancer Center have made a breakthrough in understanding how protective antibodies can target malaria parasites. By analyzing the structure of these antibodies and their interaction with the parasite's protein, the team has identified a weak spot that could be targeted by vaccines to prevent severe disease.
Researchers found that repeated mRNA vaccines enhance mucosal antibodies in nasal secretions, blocking viral entry and providing sustained protection. The immune responses generated by mRNA vaccines may persist longer than previously thought, offering hope for sustained protection against emerging COVID-19 variants.
Researchers at MIT found that a two-dose schedule for an HIV vaccine can generate a strong response to the virus, outperforming a traditional seven-dose regimen. The first dose primes the immune system, helping it to produce antibodies more effectively when a larger dose is administered one week later.
Researchers at the University of Montreal Hospital Research Centre have discovered that metformin can help deplete and eliminate viral reservoirs in people living with HIV. Metformin inhibits the mTOR molecule, slowing down HIV replication and reducing chronic inflammation.
Researchers developed a monoclonal antibody called SC27 that targets multiple parts of the SARS-CoV-2 spike protein, including conserved sections. The antibody shows promise against various COVID-19 variants and related coronaviruses, potentially benefiting immunocompromised patients
Researchers at UT Austin have developed a broadly neutralizing plasma antibody called SC27 that can neutralize all known COVID-19 variants. This discovery was made possible by the technology of Ig-Seq, which provides a closer look at the antibody response to infection and vaccination.
Researchers at Georgia State University have developed a new antibody therapy using llama-derived nanobodies that can broadly neutralize numerous strains of HIV-1. The nanobodies mimic the recognition of the CD4 receptor, offering unprecedented neutralizing abilities and potential for single-molecule treatment.
Researchers have developed a humanized mouse model with a fully functional human immune system, enabling the study of immunotherapy development, disease modeling, and vaccine development. The new model, called TruHuX, mounts specific antibody responses and can develop full-fledged systemic lupus autoimmunity.
Researchers have discovered how a neutralizing antibody blocks measles virus infection by arresting the fusion process. The study's findings may also be relevant to other viruses with pandemic potential, such as Nipah and parainfluenza viruses.
Researchers have successfully stimulated animals' immune systems to induce rare precursor B cells that can produce HIV broadly neutralizing antibodies. The findings are an encouraging step in developing a preventive HIV vaccine, targeting the challenging task of genetically diverse HIV.
Researchers at La Jolla Institute for Immunology found that people who experienced breakthrough COVID-19 infections develop T cells better equipped to recognize and target SARS-CoV-2. The study also discovered that B cells produce more diverse antibodies targeting common epitopes between the vaccine and variants.
Researchers found that repeat COVID-19 vaccinations elicit cross-reactive neutralizing antibodies capable of targeting multiple SARS-CoV-2 variants and distantly related coronaviruses. The findings suggest periodic re-vaccination may help build a stock of protective antibodies against emerging variants.
A team of scientists has developed a novel vaccine approach that induces long-lasting protective immunity against SARS-CoV-2 virus in pre-clinical models. The Clec9A-RBD antibody construct targets specific dendritic cells, leading to exceptional durability of immune responses and potential to address shortcoming of current mRNA vaccines.
Researchers found that T cells and memory B cells provide durable protection against symptomatic SARS-CoV-2 infection, with levels attainable after two doses of mRNA vaccination. The study suggests a two-dose vaccination regimen for children against COVID-19.
A Brazilian study found that a major bivalent COVID-19 vaccine induces neutralizing antibodies against the original coronavirus strain and subvariants of omicron. The vaccine's effectiveness was confirmed, but its importance in controlling disease was limited by its focus on the original strain.
Researchers have developed a DNA vaccine against zika virus that induces a strong immune response and protects mice from the virus. The vaccine uses genetic engineering to encode specific viral proteins and stimulates an adaptive immune response, with high levels of neutralizing antibodies produced.
A Swedish study reveals that neutralising antibodies to the monkeypox virus decline significantly after two doses of the MVA-BN vaccine within the first month. The findings suggest that a booster dose may be necessary to maintain immunity, emphasizing the need for scientific evidence before policy decisions are made.
A study published in Immunity identified key findings from a patient who cleared hepatitis C, revealing new insights into the development of a vaccine. The researchers found that this individual's antibodies targeted multiple regions of the virus, suggesting a potential approach to elicit a stronger immune response.
Researchers found that initial vaccinations against the ancestral SARS-CoV-2 strain shape immune responses to newer variants BA.5 and XBB, with higher B cell repertoire leading to more effective cross-reactive immunity. This 'immunological imprinting' effect could impact future vaccine designs.
A recent study found that newer monovalent COVID vaccines generated higher levels of antibodies against a range of Omicron variants, including the XBB and BQ.1.1 strains. The researchers also discovered that these vaccines increased mucosal antibody production, but not neutralizing antibody levels in the nasal cavity.
Researchers discovered an antibody that can block deadly toxins in snakes found throughout Africa, Asia, and Australia. The antibody protects against multiple snake species and has the potential to be used as a universal antivenom.
Researchers at Dartmouth's Geisel School of Medicine and Thayer School of Engineering have made significant breakthroughs in understanding how antibodies combat herpes simplex virus (HSV) infections. The study reveals that antibody effector functions play a critical role in protecting against HSV, which may lead to new treatments for n...
Researchers found a four-fold increase in immune response when people alternate arms during two-dose vaccinations. The study showed improved immunity to the original and omicron variants after three weeks and persisted beyond 13 months.
Researchers at Duke University have discovered a critical structure on the HIV virus that plays a crucial role in its infection process. By understanding this structure's dynamics, scientists may be able to design broadly neutralizing antibodies for an AIDS vaccine.
Researchers created a DNA-based vaccine that mimics the structure of a virus, inducing a strong antibody response against SARS-CoV-2. The vaccine uses a DNA scaffold carrying viral proteins, allowing the immune system to focus on the target antigen.
Research reveals memory T cells formed after Omicron breakthrough infection provide enhanced immunity against future variants. The study suggests the immune system adapts to combat emerging strains, leading to higher chances of inducing memory T cell defenses.
Three different HIV antibodies independently protected monkeys from acquiring SHIV, providing statistically significant protection and dose-dependent effect. The findings support the HIV fusion peptide as a promising preventive vaccine target.
Researchers are exploring 'priming, shaping, and polishing' techniques to develop an HIV vaccine targeting rare immune cells that produce broad-neutralizing antibodies. The Amsterdam UMC-led project aims to create an effective vaccine for low- and middle-income countries with a €4.5m grant.
Researchers at Duke-NUS Medical School have discovered a potential intranasal vaccine candidate that provides improved, longer-lasting immunity against COVID-19. The vaccine boosts mucosal antibody response and enhances long-term immune protection through preferential induction of airway-resident T cells and central memory T cells.
The Pirola variant of SARS-CoV-2 has rediscovered an entry pathway into lung cells that was previously used by earlier variants, which may promote the development of pneumonia. The virus uses the cellular enzyme TMPRSS2 for entry and is resistant to most therapeutic antibodies.
The BA.2.86 omicron subvariant can infect human lung cells more efficiently than previous omicron variants, raising concerns about potential severe disease symptoms. While bivalent mRNA vaccines can neutralize BA.2.86, the efficiency is reduced, emphasizing the importance of getting a newer booster vaccine.
Scientists have developed a new system to display epitopes in mammal cells for immunization studies, potentially speeding up the immunization process. This method allows for targeted immune responses against specific viral proteins without the need to purify antigens.
Researchers found that a breakthrough infection builds upon existing memory B cell pool and introduces random mutations that prepare antibodies for new variants. Broad neutralizing antibodies can neutralize all tested Omicron variants.
A study of over 2,300 patients found that HIV-1 neutralizing antibody response decreases over time but highly potent broadly neutralizing antibodies remain detectable. This finding suggests a possible permanent vaccine response and is an important step toward developing an effective HIV-1 vaccine.
Researchers have discovered highly effective antibodies against P. aeruginosa that can block its type III secretion system and are effective against highly resistant bacteria. These 'pathoblockers' offer a potential therapeutic approach for treating acute and chronic infections with multi-resistant pathogens.
Researchers at Duke University developed an innovative antibody approach to target and kill tumor-promoting molecules found in cancer cells. The study revealed notable reductions in tumor growth and minimal side effects, making it a promising new treatment option for various types of cancer.
Scientists have developed a trivalent vaccine candidate that provides broad and long-lasting protection against COVID-19 infection by delivering the vaccine via the nose. The vaccine triggers a strong neutralizing antibody response and protects mucosal areas, preventing disease symptoms.
A new SARS-CoV-2 variant Eris has been detected, showing an advantage in evading neutralizing antibodies and increasing infectivity. The study found that Eris is less effectively neutralized by antibodies present in the blood of vaccinated individuals or those with a previous infection.
New SARS-CoV-2 variants, such as BQ.11 and XBB.1.5, bind to cells more tightly and evade antibodies more efficiently than earlier variants, allowing reinfections and breakthrough infections. Previous infection or vaccination can generate antibodies that recognize some proteins on newer variants, reducing the risk of serious illness.
Pregnant individuals who received a full course of COVID-19 vaccination and a booster have the strongest immune protection from the disease. Boosting after previous infection increases antibody levels in both mothers and newborns, providing maximum possible protection to infants as SARS-CoV-2 evolves.
Researchers have identified a family of broadly neutralizing antibodies targeting the HIV-1 envelope protein, which may contribute to long-term remission from infection. These antibodies were found to induce the elimination of infected cells and impose a selective pressure on the virus, paving the way for new therapeutic approaches.
A new adjuvanted intranasal vaccine has shown promise in protecting both young and old mice against SARS-CoV-2 infection. The vaccine combines an RNA-based molecule with a nanoemulsion, resulting in a strong immune response.